https://orcid.org/0000-0002-6071-4393
Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ranjit Unnikrishnan, Venkatesan Radha & Viswanathan Mohan. (2021) Challenges Involved in Incorporating Personalised Treatment Plan as Routine Care of Patients with Diabetes. Pharmacogenomics and Personalized Medicine 14, pages 327-333.
Read now
Read now
Articles from other publishers (10)
Joanna Jarosz-Popek, Ceren Eyileten, Gloria M. Gager, Anna Nowak, Piotr Szwed, Zofia Wicik, Jeff Palatini, Dirk von Lewinski, Harald Sourij, Jolanta M. Siller-Matula & Marek Postula. (2023) The interaction between non-coding RNAs and SGLT2: A review. International Journal of Cardiology, pages 131419.
Crossref
Crossref
Zhang Xia, Lijuan Song, Dongdong Fang, Wenjun You, Feng Li, Deqiang Zheng, Yuhao Li, Lu Lin, Jingtao Dou, Xin Su, Qi Zhai, Yingting Zuo, Yibo Zhang, Herbert Y. Gaisano, Jiajia Jiang & Yan He. (2022) Higher systolic blood pressure is specifically associated with better islet beta-cell function in T2DM patients with high glycemic level. Cardiovascular Diabetology 21:1.
Crossref
Crossref
Zhiyue Zhu, Qi Zhang, Le Liu, Pengjie Bao, Shilin Liu, Chaoqun Song, Wenbo Yang & Zheng Nan. (2022) Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: Protocol for a systematic review and meta-analysis. Medicine 101:49, pages e31490.
Crossref
Crossref
Zofia Wicik, Anna Nowak, Joanna Jarosz-Popek, Marta Wolska, Ceren Eyileten, Jolanta M. Siller-Matula, Dirk von Lewinski, Harald Sourij, Krzysztof J. Filipiak & Marek Postuła. (2022) Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Po-Yu Chen, Chih-Chiang Chiu, Tsung-Han Hsieh, Yun-Ru Liu, Chun-Hsin Chen, Cho-Yin Huang, Mong-Liang Lu & Ming-Chyi Huang. (2022) The relationship of antipsychotic treatment with reduced brown adipose tissue activity in patients with schizophrenia. Psychoneuroendocrinology 142, pages 105775.
Crossref
Crossref
Tina Nie & Garth J. S. Cooper. (2021) Mechanisms Underlying the Antidiabetic Activities of Polyphenolic Compounds: A Review. Frontiers in Pharmacology 12.
Crossref
Crossref
Hironobu Sasaki, Yoshifumi Saisho, Jun Inaishi & Hiroshi Itoh. (2021) Revisiting Regulators of Human β-cell Mass to Achieve β-cell–centric Approach Toward Type 2 Diabetes. Journal of the Endocrine Society 5:10.
Crossref
Crossref
Hironobu Sasaki, Yoshifumi Saisho, Jun Inaishi, Yuusuke Watanabe, Tami Tsuchiya, Masayoshi Makio, Midori Sato, Masaru Nishikawa, Minoru Kitago, Taketo Yamada & Hiroshi Itoh. (2021) Reduced beta cell number rather than size is a major contributor to beta cell loss in type 2 diabetes. Diabetologia 64:8, pages 1816-1821.
Crossref
Crossref
Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, Masashi Shimoda, Tomoe Kinoshita, Taka-aki Matsuoka & Kohei Kaku. (2021) Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class. International Journal of Molecular Sciences 22:6, pages 3062.
Crossref
Crossref
Sohail Aziz, SitiMaisharah Sheikh Ghadzi, SyedAzhar Syed Sulaiman, NurHafzan Md Hanafiah & SabariahNoor Harun. (2021) Can newer anti-diabetic therapies delay the development of diabetic nephropathy?. Journal of Pharmacy And Bioallied Sciences 13:4, pages 341.
Crossref
Crossref